EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A

Alexandros Arvanitakis iD, Pål Andre Holme, Erik Berntorp iD, Jan Astermark iD

Haemophilia · 2023

DOI: 10.1111/hae.14806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Haemophilia, 2023. Verfasst von Alexandros Arvanitakis und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Translational Medicine, Lund University, Malmö, Sweden. Hauptthemen laut MEDLINE: Hemophilia A, Joint Diseases. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bayer Health Care.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

The timing of prophylaxis and F8 genotype can impact treatment outcomes in adults with severe haemophilia A (HA).

Aim

To investigate how F8 genotype, timing, and type of prophylaxis influence arthropathy, bleeding rates, factor consumption and health‐related quality of life (HRQoL).

Methods

Thirty‐eight patients with severe HA were enrolled. Bleeding events were recorded retrospectively during median 12.5 months. F8 gene variants were classified as null or non‐null. Joint health and HRQoL were assessed with HJHS and EQ‐5D‐5L, respectively.

Results

The median age at prophylaxis start was 1.25 years in the primary prophylaxis group ( N = 15, median age 26 years) and 31.5 years in the secondary group ( N = 22, 45 years), respectively. There were significant differences in the medians of HJHS (4 vs. 20, p < .001), EQ‐5D‐5L index (0.9647 vs. 0.904, p = .022), EQ VAS (87 vs. 75, p = .01) and FVIII consumption (3883 vs. 2737 IU/kg/year, p = .02), between the primary and secondary groups, respectively. Median annualized bleeding rate (ABR) was 0 for both groups. Twenty‐five null and thirteen non‐null F8 gene variants were identified. In the secondary prophylaxis group, lower median FVIII consumption (1926 vs. 3370 IU/kg/year) was shown for non‐null compared to null variants, respectively, with similar ABR and HJHS.

Conclusion

Delayed prophylaxis start with intermediate dose intensity prevents bleeds but at a cost of more arthropathy and reduced HRQoL, compared to higher intensity primary prophylaxis. Non‐null F8 genotype may allow lower factor consumption with similar HJHS and bleeding rates, compared to null genotype.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemophilia AJoint DiseasesAdultHumansFactor VIIIQuality of LifeRetrospective StudiesHemorrhageGenotype

Stichwörter der Autor:innen

F8 gene variantF8 genotypearthropathyhaemophiliahealth-related quality of lifenon-nullnullprimary prophylaxissecondary prophylaxis

Substanzen

Factor VIII

Autor:innen und Institutionen

  • Department of Translational Medicine, Lund University, Malmö, Sweden.
  • Department of Hematology, Oncology and Radiation Physics, Skåne University Hospital, Malmö, Sweden.
  • Department of Hematology, Oslo University Hospital, Oslo, Norway.
  • Institute of Clinical Medicine, University of Oslo, Oslo, Norway.

ORCID-Profile: Alexandros Arvanitakis, Erik Berntorp, Jan Astermark

Förderung

  • Bayer Health Care

Zitieren

APA

Arvanitakis, A., Holme, P. A., Berntorp, E., & Astermark, J. (2023). Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A. Haemophilia. https://doi.org/10.1111/hae.14806

Vancouver

Arvanitakis A, Holme PA, Berntorp E, Astermark J. Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A. Haemophilia. 2023. doi:10.1111/hae.14806

BibTeX
@article{Arvanitakis2023,
  author = {Arvanitakis, Alexandros and Holme, Pål Andre and Berntorp, Erik and Astermark, Jan},
  title = {Impact of timing of prophylaxis commencement, F8 genotype and age on factor consumption and health‐related quality of life in patients with severe haemophilia A},
  journal = {Haemophilia},
  year = {2023},
  doi = {10.1111/hae.14806}
}
Kostenlos starten →